COYA 203
Alternative Names: COYA-203Latest Information Update: 06 Dec 2022
At a glance
- Originator Coya Therapeutics
- Class Anti-inflammatories; Exosome therapies; Proteins; RNA
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Systemic lupus erythematosus
Most Recent Events
- 06 Dec 2022 Discontinued - Preclinical for Systemic lupus erythematosus in USA (IV)
- 10 Jun 2022 Coya Theraputics announces intention to submit IND application to USFDA for Systemic lupus erythematosus in Q2 2023
- 10 Jun 2022 Coya Therapeutics plans a phase I trial for Systemic lupus erythematosus in USA in Q4 2023.